Cholangiocarcinoma – Epidemiology – Extrapolated worldwide coverage
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key non-small-cell lung cancer patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download. Use the extended worldwide coverage data set to do the following:
- View 10-year forecasts of the first-line drug-treatable population and diagnosed incident cases for all 171 countries, stratified by region and World Bank income status.
- Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
- Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
- Generate and export global heat maps of disease risk or patient population size.
The extended worldwide coverage dashboard is available as an Excel file in the “Downloads” section. It is available only to clients with subscriptions to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact healthcare.support@clarivate.com.
Related Market Assessment Reports
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…
Report
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
